Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Glioblastoma 4Breast Neoplasms 4Brain Neoplasms 4Melanoma 3Medulloblastoma 3Ependymoma 3Unspecified Adult Solid Tumor, Protocol Specific 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Gliosarcoma 2Glioma 2Diffuse Intrinsic Pontine Glioma 2Recurrence 1Prostatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Adenocarcinoma 1

Interventions

Temozolomide 15Radiotherapy 11Everolimus 6Bevacizumab 6Irinotecan 5Cyclophosphamide 5ribociclib 4Radiation 4Panobinostat 4TIC10 compound 3Specimen Handling 3Re-Irradiation 3Etoposide 3Dasatinib 3pembrolizumab 2nimotuzumab 2abemaciclib 2Vorinostat 2Valproic Acid 2Topotecan 2Nivolumab 2Mebendazole 2Magnetic Resonance Spectroscopy 2Granulocyte-Macrophage Colony-Stimulating Factor 2Gemcitabine 2GDC-0084 2Erlotinib Hydrochloride 2Diphtheria-Tetanus Vaccine 2Cilengitide 2Cetuximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Diffuse Intrinsic Pontine Glioma × 1-methyltryptophan × Clear all
NCT04049669 2026-01-08

Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG

Augusta University

Phase 2 Active not recruiting
130 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Medulloblastoma

NCT02502708 2020-06-04

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Lumos Pharma

Phase 1 Completed
81 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡